ClinicalTrials.gg
Active, not recruitingNCT02820402Updated Sep 17, 2026

Project Viva: a Longitudinal Study of Health for the Next Generation

An observational study in Pediatric Obesity, sponsored by Harvard Pilgrim Health Care. Active, not recruiting. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Harvard Pilgrim Health Care · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,128
Ages
0 Years and older
Sex
All
01

Study summary

Project Viva is a prospective cohort study of maternal and child health, following over 2,000 mother-child pairs from the mother's pregnancy into the child's adolescence.

Read the detailed description

In 1999-2002 the Project Viva team recruited 2,670 pregnant women during their first trimester of pregnancy from eight obstetric (OB) offices of a multi-site group practice in eastern Massachusetts. 2,128 of the women had a live birth and approximately 1,600 mother-child pairs are still involved in the study. Project Viva collects data annually from multiple sources, including questionnaires, interviews, medical records, examinations, and biospecimen samples. Project Viva intends to follow participants as long as there is grant funding and interest from the participants. Some of the most beneficial health findings come from long-term follow-up.

02

Conditions studied

  • Pediatric Obesity

Keywords

  • Pregnancy
  • Obesity
  • Diet
  • Maternal/child health
  • Asthma/allergy
  • Air pollution
  • Epigenetics
  • Cognition/behavior
03

In context

Pediatric Obesity

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

This study's enrollment of 2,128 is above the median of 179 across 236 observational studies indexed under Pediatric Obesity.

Browse Pediatric Obesity studies →

Lead sponsor

Harvard Pilgrim Health Care is the lead sponsor of 35 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Mothers initially recruited during their first prenatal visit (median 9.9 wks gestation) at a multi-specialty group practice in eastern Massachusetts between 1999-2002 and their children.

Project Viva recruited 2670 women (64% of those who were approached for participation). 2,128 were still enrolled at the time of delivery and had live births, resulting in a cohort of 2,128 mother-child pairs.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Less than 22 weeks pregnant at the time of enrollment
  • Receive prenatal care at one of the selected practices
  • Plan on delivering at one of two study hospitals
  • Be able to answer questionnaires in English.

Exclusion criteria

Exclusion Criteria:

  • Multiple gestation
  • Plans to move away before delivery
  • Plans to terminate the pregnancy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,128 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Cross-sectional and longitudinal measurements of child BMI z-score in kg/m^2, standardized into a sex- and age-specific z-score using national reference data (CDC growth charts)

    The study team measures child weight and length/height at each time point, and BMI is calculated and standardized based on the child's age at the time of measurement.

    Time frame: Research measurements at birth, 6mo, early childhood (~3y), mid-childhood (~8y), early teen (~14y), and mid-late teen (~17y).

  2. Maternal post-partum weight retention, calculated as the difference between weight in kg at 1 year postpartum and pre-pregnancy weight

    Investigators obtained prenatal weights from the clinical record, and calculated total gestational weight gain (GWG) as the difference between the last weight recorded in the 4 weeks prior to delivery and pre-pregnancy weight. Project Viva mothers reported their weight at 1-year postpartum via questionnaire.

    Time frame: Before the Project Viva pregnancy and 1-year postpartum

  3. Child metabolic risk score, calculated as a standard deviation (SD) score

    Investigators derived the metabolic risk score as the mean of 5 sex- and cohort-specific z-scores for: waist circumference (cm), systolic blood pressure (SBP, calculated as the average of 5 measurements taken 1 minute apart), HDL cholesterol (mg/dL, scaled inversely), log-transformed triglycerides (mg/dL) and log-transformed HOMA-IR (calculated as fasting insulin \[μU/mL\] x fasting glucose \[mg/dL\]/405).

    Time frame: HDL-cholesterol, triglycerides, insulin, glucose and waist circumference measured at ~8y, ~14y, and ~17y of age. Blood pressure measured at birth, ~6mo, ~3y, ~8y, ~14y, and ~17y. Metabolic risk score calculated at ~8y, ~14y, and ~17y.

  4. Child neurodevelopment, assessed by continuous scores on the Wide Range Assessment of Memory and Learning, Second Edition (WRAML2), Design and Picture Memory subtests and The Kaufman Brief Intelligence Test, Second Edition (KBIT-2)

    Time frame: Children completed both the WRAML2 and the KBIT-2 at the mid-childhood visit (~8y)

  5. Mother's report of a clinical diagnosis of asthma, wheeze or reactive airway disease

    Mothers answered yes or no when asked "have you ever been told by a health care professional, such as a doctor, physician assistant or nurse practitioner, that your child has… 1. Asthma? 2. Wheezing or reactive airways? Mothers reported asthma, wheezing and reactive airways as a single outcome at the infancy visit and separately at the early and mid-childhood visits. At the early teen visit, the mother reported a diagnosis of asthma only.

    Time frame: Interviews administered at 6mo, early childhood (~3y), mid-childhood (~8y), early teen (~14y), and mid-late teen (~17y).

Secondary outcomes

  1. Child's birth length in cm

    Time frame: Measured at birth

  2. Child's birth weight in grams, standardized into a sex- and gestational age-specific z-score using national reference data

    Time frame: Measured at birth

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Harnois-Leblanc S, Rifas-Shiman SL, Switkowski KM, Perng W, Aris IM, Oken E, Young JG, Hivert MF. Estimating sex-specific population-level effects of limiting sugar-sweetened beverages or 100% fruit juices during childhood on insulin resistance, central adiposity, and glycemic outcomes in late adolescence. Am J Epidemiol. 2026 Mar 5;195(3):850-858. doi: 10.1093/aje/kwaf225. PubMed 41108089 ↗
  • Switkowski KM, Kronsteiner-Gicevic S, Rifas-Shiman SL, Lightdale JR, Oken E. Evaluation of the Prime Diet Quality Score from Early Childhood Through Mid-Adolescence. J Nutr. 2024 Jun;154(6):1890-1906. doi: 10.1016/j.tjnut.2024.04.014. Epub 2024 Apr 16. PubMed 38614240 ↗
  • Choudhary D, Rideout TC, Cameron CE, Lehman HK, Oken E, Rifas-Shiman SL, Wen X. Egg Introduction during Infancy is Associated with Lower Fat Mass Index in Females at Early Adolescence. J Nutr. 2023 Jan;153(1):158-166. doi: 10.1016/j.tjnut.2022.11.003. Epub 2022 Dec 20. PubMed 36913449 ↗
  • McGovern C, Rifas-Shiman SL, Switkowski KM, Woo Baidal JA, Lightdale JR, Hivert MF, Oken E, Aris IM. Association of cow's milk intake in early childhood with adiposity and cardiometabolic risk in early adolescence. Am J Clin Nutr. 2022 Aug 4;116(2):561-571. doi: 10.1093/ajcn/nqac103. PubMed 35441227 ↗
  • Wu AJ, Aris IM, Rifas-Shiman SL, Oken E, Taveras EM, Hivert MF. Longitudinal associations of fruit juice intake in infancy with DXA-measured abdominal adiposity in mid-childhood and early adolescence. Am J Clin Nutr. 2021 Jul 1;114(1):117-123. doi: 10.1093/ajcn/nqab043. PubMed 33829237 ↗
  • Switkowski KM, Camargo CA, Rifas-Shiman SL, Fuller H, Oken E. Early-Life Factors Are Associated with Vitamin D Status in Early and Mid-Childhood and May Differ between White and Black Children. J Nutr. 2021 May 11;151(5):1256-1268. doi: 10.1093/jn/nxaa456. PubMed 33693813 ↗
  • Turturice BA, Theorell J, Koenig MD, Tussing-Humphreys L, Gold DR, Litonjua AA, Oken E, Rifas-Shiman SL, Perkins DL, Finn PW. Perinatal granulopoiesis and risk of pediatric asthma. Elife. 2021 Feb 10;10:e63745. doi: 10.7554/eLife.63745. PubMed 33565964 ↗
  • Mahmassani HA, Switkowski KM, Scott TM, Johnson EJ, Rifas-Shiman SL, Oken E, Jacques PF. Maternal Intake of Lutein and Zeaxanthin during Pregnancy Is Positively Associated with Offspring Verbal Intelligence and Behavior Regulation in Mid-Childhood in the Project Viva Cohort. J Nutr. 2021 Mar 11;151(3):615-627. doi: 10.1093/jn/nxaa348. PubMed 33484136 ↗
  • Gingras V, Aris IM, Rifas-Shiman SL, Switkowski KM, Oken E, Hivert MF. Timing of Complementary Feeding Introduction and Adiposity Throughout Childhood. Pediatrics. 2019 Dec;144(6):e20191320. doi: 10.1542/peds.2019-1320. PubMed 31757860 ↗
  • Switkowski KM, Jacques PF, Must A, Fleisch A, Oken E. Associations of protein intake in early childhood with body composition, height, and insulin-like growth factor I in mid-childhood and early adolescence. Am J Clin Nutr. 2019 Apr 1;109(4):1154-1163. doi: 10.1093/ajcn/nqy354. PubMed 30869114 ↗
  • Gingras V, Rifas-Shiman SL, Taveras EM, Oken E, Hivert MF. Dietary behaviors throughout childhood are associated with adiposity and estimated insulin resistance in early adolescence: a longitudinal study. Int J Behav Nutr Phys Act. 2018 Dec 17;15(1):129. doi: 10.1186/s12966-018-0759-0. PubMed 30558613 ↗
  • Gingras V, Rifas-Shiman SL, Derks IPM, Aris IM, Oken E, Hivert MF. Associations of Gestational Glucose Tolerance With Offspring Body Composition and Estimated Insulin Resistance in Early Adolescence. Diabetes Care. 2018 Dec;41(12):e164-e166. doi: 10.2337/dc18-1490. Epub 2018 Oct 16. No abstract available. PubMed 30327360 ↗
  • Switkowski KM, Jacques PF, Must A, Hivert MF, Fleisch A, Gillman MW, Rifas-Shiman S, Oken E. Higher Maternal Protein Intake during Pregnancy Is Associated with Lower Cord Blood Concentrations of Insulin-like Growth Factor (IGF)-II, IGF Binding Protein 3, and Insulin, but Not IGF-I, in a Cohort of Women with High Protein Intake. J Nutr. 2017 Jul;147(7):1392-1400. doi: 10.3945/jn.117.250589. Epub 2017 Jun 7. PubMed 28592512 ↗
  • Switkowski KM, Jacques PF, Must A, Kleinman KP, Gillman MW, Oken E. Maternal protein intake during pregnancy and linear growth in the offspring. Am J Clin Nutr. 2016 Oct;104(4):1128-1136. doi: 10.3945/ajcn.115.128421. Epub 2016 Aug 31. PubMed 27581477 ↗

Individual participant data

Plan to share: Yes — Project Viva protocols include a data sharing plan. The process for requesting data is detailed in the study policy document, available on the Project Viva website: https://www.hms.harvard.edu/viva/policies-for-using-our-data.pdf.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 1999 (actual). Primary completion is estimated for Apr 2028, 351 months after the start.

Of 94 non-industry observational studies under Pediatric Obesity, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 132. This study's planned 351 months is above that.

Counting every sponsor, half of 96 studies reached it within 52 months; a quarter within 21 and three quarters within 157.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2016
First posted
Jul 1, 2016
StartActual
Jan 1999
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02820402
Lead sponsor
Harvard Pilgrim Health Care
Responsible party
Sponsor
First posted
Jul 1, 2016
Start date
Jan 1999
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 17, 2026

Study contacts

Emily Oken, MD, MPH
principal investigator · Harvard Medical School / Harvard Pilgrim Health Care Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion